Skip to main content
Journal cover image

Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.

Publication ,  Journal Article
Myat, A; Ahmad, Y; Haldar, S; Tantry, US; Redwood, SR; Gurbel, PA; Lip, GY
Published in: Expert Rev Cardiovasc Ther
August 2013

Current European atrial fibrillation (AF) guidelines have assigned a strong recommendation for the initiation of antithrombotic therapy to prevent thromboembolism in all but those AF patients at low risk (or with contraindications). Furthermore, the selection of antithrombotic therapy is based on the absolute risks of thromboembolism and bleeding, and the relative risk and benefit for a given patient. By their very mechanism of action, antithrombotic agents used for stroke prevention in AF will potentially increase the risk of bleeding events. Moreover, the introduction of novel oral anticoagulation agents have introduced new, hitherto ill-defined, deficiencies in the authors' knowledge with respect to anticoagulation monitoring, availability of direct antidotes, drug-drug interactions and the ability to appropriately control and reverse their actions if bleeding events occur. The authors present a comprehensive review on all aspects of bleeding related to currently licensed antithrombotic agents used for stroke prevention in patients with AF.

Duke Scholars

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

August 2013

Volume

11

Issue

8

Start / End Page

1029 / 1049

Location

England

Related Subject Headings

  • Thromboembolism
  • Stroke
  • Risk Factors
  • Practice Guidelines as Topic
  • Humans
  • Hemorrhage
  • Fibrinolytic Agents
  • Europe
  • Drug Interactions
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Myat, A., Ahmad, Y., Haldar, S., Tantry, U. S., Redwood, S. R., Gurbel, P. A., & Lip, G. Y. (2013). Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther, 11(8), 1029–1049. https://doi.org/10.1586/14779072.2013.815423
Myat, Aung, Yousif Ahmad, Shouvik Haldar, Udaya S. Tantry, Simon R. Redwood, Paul A. Gurbel, and Gregory Yh Lip. “Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.Expert Rev Cardiovasc Ther 11, no. 8 (August 2013): 1029–49. https://doi.org/10.1586/14779072.2013.815423.
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, et al. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1029–49.
Myat, Aung, et al. “Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.Expert Rev Cardiovasc Ther, vol. 11, no. 8, Aug. 2013, pp. 1029–49. Pubmed, doi:10.1586/14779072.2013.815423.
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1029–1049.
Journal cover image

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

August 2013

Volume

11

Issue

8

Start / End Page

1029 / 1049

Location

England

Related Subject Headings

  • Thromboembolism
  • Stroke
  • Risk Factors
  • Practice Guidelines as Topic
  • Humans
  • Hemorrhage
  • Fibrinolytic Agents
  • Europe
  • Drug Interactions
  • Cardiovascular System & Hematology